ALLR — Allarity Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1860657 ·
Last close
$0.84
Market Cap
$13.38M
52W High
$1.84
52W Low
$0.77
ADV30
146,902
Next earnings
—
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -2,671,000 -3,405,000 32,115,000 16,982,000 28,579,000
Mar 2026 25,000 — -2,688,000 -2,750,000 34,923,000 19,812,000 28,003,000
Dec 2025 320,000 — -2,918,000 -3,373,000 18,258,000 14,687,000 8,430,000
Sep 2025 0 — -2,518,000 -2,806,000 20,796,000 16,895,000 8,785,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-13,710,000
Investing CF
$-64,000
Financing CF
$21,810,000
CapEx
$-64,000
Dividends Paid
—
Buybacks
$-887,000
EPS Diluted TTM
$-0.72
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-136,352,000
Inventory
—
Receivables
$1,310,000
ST Investments
—
EBIT TTM
$-11,270,000
Pretax Income TTM
$-12,334,000
Interest Exp TTM
$1,064,000
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$345,000
EBITDA
$-10,801,000
Free Cash Flow
$-19,769,876
Enterprise Value
$20,479,648
Total Cash
$16,982,000
Total Debt
$22,286,000
Shares Out
15,910,724
Trailing EPS
$-0.79
Book Value
$0.52
ROE
-157.1%
ROA
-25.3%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 320,000 -12,605,000 -11,231,000 18,258,000 8,430,000 9,828,000 -14,820,000
Dec 2024 0 -17,538,000 -24,515,000 22,650,000 10,839,000 11,811,000 -17,352,000
Dec 2023 0 -17,129,000 -11,901,000 11,862,000 14,613,000 -2,751,000 -12,745,000
Dec 2022 0 -16,892,000 -16,058,000 14,544,000 12,654,000 1,890,000 -16,817,000

TTM Snapshot

Revenues TTM
$-114,000
NetIncome TTM
$-12,334,000
OpCashFlow TTM
—
Assets (Latest)
$32,115,000
Forward EPS
$-0.86

Peers — same industry

TickerNameMarket CapLastDaily %
TVRD Tvardi Therapeutics, Inc. $13.47M $1.01 —
SYBX SYNLOGIC, INC. $13.47M $1.10 —
ONCO Onconetix, Inc. $13.14M $3.00 —
AKTX Akari Therapeutics Plc $13.03M $5.70 —
ACTU ACTUATE THERAPEUTICS, INC. $13.84M $0.25 —

News headlines (Yahoo Finance, 1h cache)

Allarity Therapeutics Granted U.S. Patent for Stenoparib’s Clinical Dosing Regimen, with Protection Into 2045
2026-11-18 12:50 · Yahoo
Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts
2026-11-16 12:50 · Yahoo
Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance
2026-11-13 13:05 · Yahoo
Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue
2026-10-30 11:45 · Yahoo
Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock Now
2026-10-09 12:55 · Yahoo
New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod
2026-10-05 12:30 · Yahoo
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development
2026-09-30 13:00 · Yahoo
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
2026-09-28 12:00 · Yahoo
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
2026-09-15 12:00 · Yahoo
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
2026-08-14 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.